April 4, 2024- Teleflex Incorporated announced the upcoming full market release of the Advanced Tissue Control (ATC) feature on its unified UroLift™ 2 System platform designed for the treatment of benign prostatic hyperplasia (BPH) symptoms in men with all prostate types up to 100g. The UroLift™ 2 System with Advanced Tissue Control (UroLift™ 2 ATC) has received FDA clearance, marking a significant advancement in BPH care.
The UroLift™ 2 System is a market leader and proven minimally invasive treatment for BPH that provides an effective alternative to BPH medications and major surgery.The UroLift™ 2 ATC represents a breakthrough in BPH treatment, with its adaptable design that enables physicians to customize treatments to each patient’s unique anatomy and allows a personalized approach to help maximize effectiveness.
The UroLift™ 2 ATC System offers physicians enhanced confidence, improved control of obstructive tissue and targeting accuracy through tissue control wings and laser-etched needle markers designed to make tissue manipulation and implant delivery more precise.